

Radioligand treatment program investment considerations*

Use the list in this document to understand the potential costs that may be associated with setting up and maintaining a radioligand treatment program at your organization. Each section includes a total costs field, which can help you understand the one-time costs and recurring costs.

Initial Setup: One-Time Costs	
	Cost estimate
Hot laboratory	
• Dose calibrator and appropriate accessories	
• Dose preparation area	
• Other laboratory equipment (survey meter, tongs, etc)	
• Appropriate shielding for infusion (eg, syringe shields, lead bricks, L-blocks, etc)	
Infusion room	
• Designated infusion room	
• Necessary equipment	
• Necessary supplies for infusion	
Bathroom	
• Dedicated space or not accessible to general public	
Initial Setup Costs Total	

Recurring Costs	
	Cost estimate
Staffing	
• Authorized user (remote/onsite)	
• Radiation safety officer (may be contracted out)	
• Other support staff (eg, technologist, nurse)	
Licensing	
• Approved isotope part of RAM license (separate cost if RAM license needs amending)	
• Adequate possession limit part of RAM license (separate cost if RAM license needs amending)	
• Timely renewal letter (if necessary)	
Recurring Costs Total	

Potential Total Cost (Year 1) Note: Costs for year 2 and onward likely to be lower	
--	--

RAM, radioactive materials.

*These may not be all the potential costs associated with radioligand treatment program setup and maintenance. Novartis cannot guarantee that costs resulting from these calculations are accurate.

See next page for other important considerations

Other important considerations



SOPs and documentation

- RLT infusion standard operating procedure (SOP)
- Extravasation SOP
- NET hormonal crisis SOP (for LUTATHERA® [lutetium Lu 177 dotatate] only)
- RAM spill SOP
- Treatment consent
- Written directive
- Patient discharge instruction
- Patient release assessment



Training and education

- Chemical form (if necessary, by state)
- Dose calibrator dial setting verification
- Product radiation safety discussion
- Appropriate shielding for infusion



Waste management (not applicable to prefilled syringe*)

- Appropriate waste shielding
- Adequate waste storage space
- Disposal for Lu-177m (if applicable)



Referral pathway

NET, neuroendocrine tumor; RLT, radioligand therapy.

*Prefilled syringe is only available for PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) at this time.